Mereo BioPharma Group PLC (MREO)
3.20
-0.07
(-2.14%)
USD |
NASDAQ |
May 17, 16:00
3.20
0.00 (0.00%)
After-Hours: 20:00
Mereo BioPharma Group Research and Development Expense (Quarterly): 3.994M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 3.994M |
| June 30, 2023 | 4.655M |
| Date | Value |
|---|---|
| March 31, 2023 | 5.307M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.994M
Minimum
Mar 2024
5.307M
Maximum
Mar 2023
4.652M
Average
4.655M
Median
Jun 2023
Research and Development Expense (Quarterly) Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| NuCana PLC | 8.519M |
| TC BioPharm (Holdings) PLC | -- |
| Adaptimmune Therapeutics PLC | 35.21M |
| Autolus Therapeutics PLC | 25.16M |